Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2015

01.06.2015 | Epidemiology

Body mass index associated with genome-wide methylation in breast tissue

verfasst von: Brionna Y. Hair, Zongli Xu, Erin L. Kirk, Sophia Harlid, Rupninder Sandhu, Whitney R. Robinson, Michael C. Wu, Andrew F. Olshan, Kathleen Conway, Jack A. Taylor, Melissa A. Troester

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Gene expression studies indicate that body mass index (BMI) is associated with molecular pathways involved in inflammation, insulin-like growth factor activation, and other carcinogenic processes in breast tissue. The goal of this study was to determine whether BMI is associated with gene methylation in breast tissue and to identify pathways that are commonly methylated in association with high BMI. Epigenome-wide methylation profiles were determined using the Illumina HumanMethylation450 BeadChip array in the non-diseased breast tissue of 81 women undergoing breast surgery between 2009 and 2013 at the University of North Carolina Hospitals. Multivariable, robust linear regression was performed to identify methylation sites associated with BMI at a false discovery rate q value <0.05. Gene expression microarray data was used to identify which of the BMI-associated methylation sites also showed correlation with gene expression. Gene set enrichment analysis was conducted to assess which pathways were enriched among the BMI-associated methylation sites. Of the 431,568 methylation sites analyzed, 2573 were associated with BMI (q value <0.05), 57 % of which showed an inverse correlation with BMI. Pathways enriched among the 2573 probe sites included those involved in inflammation, insulin receptor signaling, and leptin signaling. We were able to map 1251 of the BMI-associated methylation sites to gene expression data, and, of these, 226 (18 %) showed substantial correlations with gene expression. Our results suggest that BMI is associated with genome-wide methylation in non-diseased breast tissue and may influence epigenetic pathways involved in inflammatory and other carcinogenic processes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
9.
11.
Zurück zum Zitat Enger SM, Ross RK, Paganini-Hill A et al (2000) Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomark Prev 9(7):681–687 Enger SM, Ross RK, Paganini-Hill A et al (2000) Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomark Prev 9(7):681–687
12.
Zurück zum Zitat Suga K, Imai K, Eguchi H et al (2001) Molecular significance of excess body weight in postmenopausal breast cancer patients, in relation to expression of insulin-like growth factor I receptor and insulin-like growth factor II genes. Jpn J Cancer Res 92(2):127–134CrossRefPubMed Suga K, Imai K, Eguchi H et al (2001) Molecular significance of excess body weight in postmenopausal breast cancer patients, in relation to expression of insulin-like growth factor I receptor and insulin-like growth factor II genes. Jpn J Cancer Res 92(2):127–134CrossRefPubMed
15.
Zurück zum Zitat Parrizas M, Saltiel AR, LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272(1):154–161CrossRefPubMed Parrizas M, Saltiel AR, LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272(1):154–161CrossRefPubMed
19.
Zurück zum Zitat Sandoval J, Heyn H, Moran S et al (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6(6):692–702CrossRefPubMed Sandoval J, Heyn H, Moran S et al (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6(6):692–702CrossRefPubMed
21.
Zurück zum Zitat Handle Illumina methylation data. R package Handle Illumina methylation data. R package
22.
Zurück zum Zitat 1000 Genomes Project Consortium, Abecasis GR, Auton A et al (2012) An integrated map of genetic variation from 1092 human genomes. Nature 491(7422):56–65. doi:10.1038/nature11632 CrossRef 1000 Genomes Project Consortium, Abecasis GR, Auton A et al (2012) An integrated map of genetic variation from 1092 human genomes. Nature 491(7422):56–65. doi:10.​1038/​nature11632 CrossRef
23.
Zurück zum Zitat Price ME, Cotton AM, Lam LL et al. (2013) Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin. 6(1):4,8935-6-4. doi: 10.1186/1756-8935-6-4 Price ME, Cotton AM, Lam LL et al. (2013) Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin. 6(1):4,8935-6-4. doi: 10.​1186/​1756-8935-6-4
26.
Zurück zum Zitat NCBI News, September (2009) Bethesda (MD), National Center for Biotechnology Information (US), 2009 NCBI News, September (2009) Bethesda (MD), National Center for Biotechnology Information (US), 2009
29.
Zurück zum Zitat Saxonov S, Berg P, Brutlag DL (2006) A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103(5):1412–1417CrossRefPubMedCentralPubMed Saxonov S, Berg P, Brutlag DL (2006) A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103(5):1412–1417CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Price ME, Cotton AM, Lam LL, et al (2013) Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenet Chromatin 6(1):4,8935-6-4. doi: 10.1186/1756-8935-6-4 Price ME, Cotton AM, Lam LL, et al (2013) Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenet Chromatin 6(1):4,8935-6-4. doi: 10.​1186/​1756-8935-6-4
38.
Zurück zum Zitat Singh A, Purohit A, Ghilchik MW et al (1999) The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 6(2):139–147CrossRefPubMed Singh A, Purohit A, Ghilchik MW et al (1999) The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 6(2):139–147CrossRefPubMed
39.
Zurück zum Zitat Zhao Y, Nichols JE, Valdez R et al (1996) Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 10(11):1350–1357PubMed Zhao Y, Nichols JE, Valdez R et al (1996) Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 10(11):1350–1357PubMed
40.
Zurück zum Zitat Kitawaki J, Kusuki I, Koshiba H et al (1999) Leptin directly stimulates aromatase activity in human luteinized granulosa cells. Mol Hum Reprod 5(8):708–713CrossRefPubMed Kitawaki J, Kusuki I, Koshiba H et al (1999) Leptin directly stimulates aromatase activity in human luteinized granulosa cells. Mol Hum Reprod 5(8):708–713CrossRefPubMed
41.
Zurück zum Zitat Magoffin DA, Weitsman SR, Aagarwal SK et al (1999) Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. Ginekol Pol 70(1):1–7PubMed Magoffin DA, Weitsman SR, Aagarwal SK et al (1999) Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. Ginekol Pol 70(1):1–7PubMed
43.
Zurück zum Zitat Casbas-Hernandez P, D’Arcy M, Roman-Perez E et al (2013) Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res 15(5):R82CrossRefPubMedCentralPubMed Casbas-Hernandez P, D’Arcy M, Roman-Perez E et al (2013) Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res 15(5):R82CrossRefPubMedCentralPubMed
49.
Zurück zum Zitat Trujillo KA, Heaphy CM, Mai M et al (2011) Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 129(6):1310–1321. doi:10.1002/ijc.25788 CrossRefPubMedCentralPubMed Trujillo KA, Heaphy CM, Mai M et al (2011) Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 129(6):1310–1321. doi:10.​1002/​ijc.​25788 CrossRefPubMedCentralPubMed
50.
Zurück zum Zitat Heaphy CM, Bisoffi M, Fordyce CA et al (2006) Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 119(1):108–116. doi:10.1002/ijc.21815 CrossRefPubMed Heaphy CM, Bisoffi M, Fordyce CA et al (2006) Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 119(1):108–116. doi:10.​1002/​ijc.​21815 CrossRefPubMed
Metadaten
Titel
Body mass index associated with genome-wide methylation in breast tissue
verfasst von
Brionna Y. Hair
Zongli Xu
Erin L. Kirk
Sophia Harlid
Rupninder Sandhu
Whitney R. Robinson
Michael C. Wu
Andrew F. Olshan
Kathleen Conway
Jack A. Taylor
Melissa A. Troester
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3401-8

Weitere Artikel der Ausgabe 2/2015

Breast Cancer Research and Treatment 2/2015 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.